文献速递胸部肿瘤支持与姑息治疗

晚期中央型肺部肿瘤姑息性放疗中主动保护食管的PROACTIVE 3期随机临床试验

Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

PROACTIVE多中心3期随机试验纳入90例III/IV期NSCLC需姑息胸部放疗患者,1:1随机至标准放疗或食管保护调强放疗(ES-IMRT)。放疗后2周食管生活质量评分两组差异未达统计学显著(P=.06),但ES-IMRT显著降低症状性放射性食管炎发生率(24% vs 2%,P=.002)。

要点

  • ES-IMRT未显著改善2周食管生活质量评分(P=.06)
  • ES-IMRT显著降低症状性放射性食管炎发生率(24% vs 2%,P=.002)
  • 事后亚组分析中30 Gy组食管炎减少最明显(30% vs 0%,P=.004)

核心结论

  • ES-IMRT未显著改善食管生活质量,但显著降低症状性食管炎发生率。
  • 事后分析显示30 Gy放疗时食管炎减少最明显,提示处方剂量较高时ES-IMRT可能获益最大。

研究设计与样本

  • PROACTIVE为多中心3期随机临床试验,2016年6月24日至2019年3月6日入组。
  • 6个三级学术癌症中心共90例III/IV期NSCLC患者,适合姑息胸部放疗(20 Gy/5次或30 Gy/10次)。
  • 患者1:1随机至标准放疗(对照臂)或ES-IMRT,随访至多1年,采用意向性分析。
  • ES-IMRT通过牺牲靶区覆盖确保食管最大剂量不超过处方剂量的80%。

主要发现

  • 放疗后2周食管癌分量表平均(SD)评分:对照臂50.5(10.2)(95%CI 47.2-53.8)vs ES-IMRT臂54.3(7.6)(95%CI 51.9-56.7),P=.06。
  • 症状性放射性食管炎发生率:对照臂24%(n=11)vs ES-IMRT臂2%(n=1),P=.002。
  • 事后按分层因素亚组分析:30 Gy组食管炎发生率30%(n=8)vs 0%,P=.004。
  • 总生存两组相似:标准放疗中位8.6个月(95%CI 5.7-15.6)vs ES-IMRT中位8.7个月(95%CI 5.1-10.2),P=.62。

关键数值与推荐

  • 主要终点为放疗后2周食管生活质量,采用食管癌分量表评估,2-3分变化视为临床有意义。
  • 食管癌分量表评分越高表示生活质量越好。
  • 放疗方案为20 Gy/5次或30 Gy/10次。

临床怎么用

  • 作者认为ES-IMRT在处方剂量较高(30 Gy)时可能获益最大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Palliative thoracic radiotherapy (RT) can alleviate local symptoms associated with advanced non-small cell lung cancer (NSCLC), but esophagitis is a common treatment-related adverse event. Whether esophageal-sparing intensity-modulated RT (ES-IMRT) achieves a clinically relevant reduction in esophageal symptoms remains unclear. OBJECTIVE: To examine whether ES-IMRT achieves a clinically relevant reduction in esophageal symptoms compared with standard RT. DESIGN, SETTING, AND PARTICIPANTS: Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE) is a multicenter phase 3 randomized clinical trial that enrolled patients between June 24, 2016, and March 6, 2019. Data analysis was conducted from January 23, 2020, to October 22, 2021. Patients had up to 1 year of follow-up. Ninety patients at 6 tertiary academic cancer centers who had stage III/IV NSCLC and were eligible for palliative thoracic RT (20 Gy in 5 fractions or 30 Gy in 10 fractions) were included. INTERVENTIONS: Patients were randomized (1:1) to standard RT (control arm) or ES-IMRT. Target coverage was compromised to ensure the maximum esophagus dose was no more than 80% of the RT prescription dose. MAIN OUTCOMES AND MEASURES: The primary outcome was esophageal quality of life (QOL) 2 weeks post-RT, measured by the esophageal cancer subscale (ECS) of the Functional Assessment of Cancer Therapy: Esophagus questionnaire. Higher esophageal cancer subscale scores correspond with improved QOL, with a 2- to 3-point change considered clinically meaningful. Secondary outcomes included overall survival, toxic events, and other QOL metrics. Intention-to-treat analysis was used. RESULTS: Between June 24, 2016, and March 6, 2019, 90 patients were randomized to standard RT or ES-IMRT (median age at randomization, 72.0 years [IQR, 65.6-80.3]; 50 [56%] were female). Thirty-six patients (40%) received 20 Gy and 54 (60%) received 30 Gy. For the primary end point, the mean (SD) 2-week ECS score was 50.5 (10.2) in the control arm (95% CI, 47.2-53.8) and 54.3 (7.6) in the ES-IMRT arm (95% CI, 51.9-56.7) (P = .06). Symptomatic RT-associated esophagitis occurred in 24% (n = 11) of patients in the control arm vs 2% (n = 1) in the ES-IMRT arm (P = .002). In a post hoc subgroup analysis based on the stratification factor, reduction in esophagitis was most evident in patients receiving 30 Gy (30% [n = 8] vs 0%; P = .004). Overall survival was similar with standard RT (median, 8.6; 95% CI, 5.7-15.6 months) and ES-IMRT (median, 8.7; 95% CI, 5.1-10.2 months) (P = .62). CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, ES-IMRT did not significantly improve esophageal QOL but significantly reduced the incidence of symptomatic esophagitis. Because post hoc analysis found that reduced esophagitis was most evident in patients receiving 30 Gy of RT, these findings suggest that ES-IMRT may be most beneficial when the prescription dose is higher (30 Gy). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02752126.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Louie AV, Granton PV, Fairchild A, et al. Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35201290. doi:10.1001/jamaoncol.2021.7664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。